Supernus Pharmaceuticals, Inc.

NasdaqGM:SUPN Stock Report

Market Cap: US$2.0b

Supernus Pharmaceuticals Management

Management criteria checks 2/4

Supernus Pharmaceuticals' CEO is Jack Khattar, appointed in Jan 2005, has a tenure of 19.83 years. total yearly compensation is $13.28M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 3.53% of the company’s shares, worth $69.23M. The average tenure of the management team and the board of directors is 9.6 years and 12.3 years respectively.

Key information

Jack Khattar

Chief executive officer

US$13.3m

Total compensation

CEO salary percentage7.3%
CEO tenure19.8yrs
CEO ownership3.5%
Management average tenure9.6yrs
Board average tenure12.3yrs

Recent management updates

Recent updates

Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth

Nov 12

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk

Oct 31
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Sep 12

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Aug 19
Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Mar 04

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Feb 03
Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19
These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Oct 10

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Aug 19

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Aug 16
Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Supernus: A Work In Progress

Jul 29

Supernus: New Beginnings

Mar 28

CEO Compensation Analysis

How has Jack Khattar's remuneration changed compared to Supernus Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$60m

Jun 30 2024n/an/a

US$5m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$13mUS$963k

US$1m

Sep 30 2023n/an/a

US$26m

Jun 30 2023n/an/a

US$43m

Mar 31 2023n/an/a

US$52m

Dec 31 2022US$10mUS$914k

US$61m

Sep 30 2022n/an/a

US$38m

Jun 30 2022n/an/a

US$57m

Mar 31 2022n/an/a

US$73m

Dec 31 2021US$8mUS$870k

US$53m

Sep 30 2021n/an/a

US$82m

Jun 30 2021n/an/a

US$100m

Mar 31 2021n/an/a

US$111m

Dec 31 2020US$7mUS$836k

US$127m

Sep 30 2020n/an/a

US$129m

Jun 30 2020n/an/a

US$118m

Mar 31 2020n/an/a

US$116m

Dec 31 2019US$8mUS$812k

US$113m

Sep 30 2019n/an/a

US$106m

Jun 30 2019n/an/a

US$105m

Mar 31 2019n/an/a

US$103m

Dec 31 2018US$7mUS$724k

US$111m

Sep 30 2018n/an/a

US$99m

Jun 30 2018n/an/a

US$87m

Mar 31 2018n/an/a

US$73m

Dec 31 2017US$6mUS$614k

US$57m

Compensation vs Market: Jack's total compensation ($USD13.28M) is above average for companies of similar size in the US market ($USD5.35M).

Compensation vs Earnings: Jack's compensation has increased by more than 20% in the past year.

CEO

Jack Khattar (63 yo)

19.8yrs

Tenure

US$13,278,093

Compensation

Mr. Jack A. Khattar, M.B.A., founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as Chief Executive Officer, President, Secretary and Director since 2005. He...

Leadership Team

NamePositionTenureCompensationOwnership
Jack Khattar
Founder19.8yrsUS$13.28m3.53%
$ 69.2m
Timothy Dec
Senior VP & CFO3.3yrsUS$2.38m0.013%
$ 255.4k
Padmanabh Bhatt
Chief Scientific Officer & Senior VP of Intellectual Property12.7yrsUS$1.47m0.018%
$ 343.9k
Frank Mottola
Senior Vice President of Quality4.8yrsUS$1.79m0.015%
$ 291.3k
Jonathan Rubin
Senior VP of Research & Development and Chief Medical Officer4.8yrsUS$1.59m0.0084%
$ 164.8k
Kevin Anderson
Compliance Officer12.8yrsno datano data
Todd Horich
Senior Vice President of Marketing9.8yrsno datano data
Taylor Raiford
Senior Vice President of Sales9.8yrsno datano data
Bryan Roecklein
Senior Vice President of Corporate Development9.3yrsno datano data
Jeff Bozick
Senior Vice President of Supply Chain3.5yrsno datano data

9.6yrs

Average Tenure

63yo

Average Age

Experienced Management: SUPN's management team is seasoned and experienced (9.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jack Khattar
Founder19.8yrsUS$13.28m3.53%
$ 69.2m
Charles Newhall
Independent Chairman of the Board19.8yrsUS$407.02k0.24%
$ 4.6m
Georges Gemayel
Independent Director9.7yrsUS$378.52k0.024%
$ 473.0k
Carrolee Barlow
Independent Director6.4yrsUS$376.02k0.031%
$ 611.1k
Frederick Hudson
Independent Director14.8yrsUS$385.02k0.051%
$ 1.0m
Bethany Sensenig
Directorless than a yearUS$514.39kno data

12.3yrs

Average Tenure

63.5yo

Average Age

Experienced Board: SUPN's board of directors are seasoned and experienced ( 12.3 years average tenure).